Although CXCR4 antagonists have already been tested in clinical trials in other type of cancers, demonstrating that blocking CXCL12 binding to CXCR4 can interfere with cancer progression [35,36], specific blockers of CXCL12 production are still lacking. This evidence concerns the gene CXCL12 and cancer.